Abstract
DNA adduct formation is an important initial event in chemicalcarcinogenesis. Metabolic activation and deactivation pathways are involved in aromatic amine carcinogenesis, and genetic polymorphism in the N-acetyltransferase 2 (NAT2) gene is associated with differential susceptibility to cancer from aromatic amine chemicals. In the present study, aromatic amine-DNA adduct levels were measured in rapid (Bio. 82.73/H-Patr) and slow (Bio. 82.73/H-Pats) acetylator Syrian hamsters congenic at the NAT2 locus following a single injection of 2-aminofluorene (60 mg/kg). The major DNA adduct, N-(deoxyguanosin-8-yl)-2-aminofluorene (C8-AF), was detected and quantitated by 32P-postlabeling assay at 6, 18, 24, 36, and 48 hr postinjection. Peak levels of C8-AF were achieved at 18-36 hr post-injection in both rapid and slow acetylators. C8-AF levels were significantly higher in tumor-target organs (liver and urinary bladder) than in nontarget organs (heart, colon, and prostate). Significant differences in C8-AF levels between rapid and slow acetylators in liver, heart, colon, and prostate were not observed. However, C8-AF levels in urinary bladder were significantly (four-fold) higher in rapid versus slow acetylators. These results suggest that 2-aminofluorene forms significantly higher levels of DNA adducts in tumor-target organs than in non-target organs and that acetyltransferase polymorphism plays a significant role in 2-aminofluorene-DNA adduct formation in urinary bladder of Syrian hamster.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.